Cohance Lifesciences Limited
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.
What Cohance files
- Investor Meet53
- Others52
- Updates27
- Important20
- PPTs7
- Board Meeting7
Cohance Lifesciences' Shamshabad plant received 4 USFDA observations after an inspection. The company has initiated corrective actions and will respond, reaffirming its commitment to quality and compliance.
Cohance Lifesciences advances its ADC strategy with a USD 13 million additional investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio. This reorganisation, funded by internal accruals, strengthens integration and pipeline development.
Cohance Lifesciences' committee has approved strategic investments totaling USD 18 million to strengthen its Antibody-drug Conjugate (ADC) strategy. The company will acquire additional shares in its subsidiary NJ Bio for approximately USD 13 million, increasing its stake from 56% to 67.3%. This aims for closer integration of NJ Bio’s services...
Cohance Lifesciences will attend the Ashwamedh - Elara India Dialogue 2026 conference in Mumbai on September 1, 2026. Management will participate in group and one-on-one meetings, where no unpublished price-sensitive information will be shared.
Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication